<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2604">
  <stage>Registered</stage>
  <submitdate>7/12/2009</submitdate>
  <approvaldate>7/12/2009</approvaldate>
  <nctid>NCT01028261</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study, to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZGN-433 in Obese Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ZAF-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ZGN-433

Experimental: ZGN-433 - 

Placebo Comparator: Normal Saline - 


Treatment: drugs: ZGN-433
Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Measures of the safety and tolerability of ZGN-433 include documentation of adverse events and changes (compared to baseline) in vital signs, physical examination, heart rhythm, and laboratory tests.</outcome>
      <timepoint>Approximately 2 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Weight</outcome>
      <timepoint>Approximately 2 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Obese, otherwise healthy females

          -  Post menopausal or infertile

          -  Weight = 50 kg

          -  BMI = 32 and = 45 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Use of weight loss agents in the past month

          -  History of eating disorder

          -  History of diabetes or other endocrine disorder

          -  History of gastric bypass

          -  Current smokers

          -  Unstable body weight during the past 3 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>31</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>Q-Pharm Clinics, Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <hospital>Nucleus Network - Heidelberg</hospital>
    <postcode>4006 - Brisbane</postcode>
    <postcode>3084 - Heidelberg</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Zafgen, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess whether multiple doses of ZGN-433 is safe and well
      tolerated in obese female subjects. The study will also provide information on how much
      ZGN-433 gets into the blood, how long does it stay in the body, and how it affects other
      biological markers.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01028261</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>James E Vath, PhD</name>
      <address>Zafgen, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>